Downloading...
Download

Vikingtherapeutics

VKTX: Unusual Options Flow & a Breakthrough Weight-Loss DrugIf you haven`t bought CKTX before the recent rally: Now you need to know that Viking Therapeutics (VKTX) is a speculative biotech stock in the GLP-1/GIP agonist space, aiming to challenge market leaders like Eli Lilly and Novo Nordisk. Recently, I noticed unusual options flow — specifically, Jan 16, 2026 $60 strike calls Key Bullish Points 1) Riding the Obesity Drug Boom VK2735 is Viking’s dual agonist candidate showing promising early weight-loss efficacy, with potential overlap benefits in NASH (liver disease). The obesity treatment space is expected to exceed $100B by 2030—huge upside if their trials continue positively. 2) Options Flow Tells a Story Those Jan 2026 $60 calls caught my attention precisely because the stock currently trades in the mid-$60s. These aren’t cheap lottery plays—they’re strategically timed wrt trial readouts, partnerships, or acquisition interest. Essentially, someone anticipates meaningful upside in the near future. 3) Descending Wedge — Chart Looks Bullish VKTX peaked near $100, then pulled back into a well-defined descending wedge. If it breaks out above $70–$72 with volume, that could kick off a classic reversal trade. Smart Money Options Flow — Near-Term Bet: Recently, I spotted unusual open interest in $60 strike calls expiring Jan 16, 2026 — that’s only about 7 months away. This means someone is positioning for a big upside move relatively soon, likely betting on positive Phase 2b/3 data, a partnership deal, or even buyout chatter within the next few quarters. Short-dated, out-of-the-money call flow like this often hints at near-term news — not just a long-dated hedge.
NASDAQ:VKTXLong
by TopgOptions
$VKTX is about to FEAST! Don't miss out on this BioTech trade. 🚀 Here it is: Your Free Saturday Setup! 🚀 Just as promised, here is a detailed video analysis on NASDAQ:VKTX Viking Therapeutics! 🧬 This trade meets all the criteria of my "High Five Setup" trading strategy, backed by solid technical analysis. Also, it has the potential to return over 100% on your capital deployed. With more probabilities on our side, the likelihood of success is through the roof! 📈💥 Check it out, and let’s ride this wave together! 🌊 Stay tuned for more insights! 🔔 NFA #Trading #StockMarket #Biotech #Investing #HighFiveSetup
NASDAQ:VKTXLong
by RonnieV29
41
Viking Therapeutics Surges 25% Amidst Weight Loss Pill Data In a remarkable turn of events, Viking Therapeutics ( NASDAQ:VKTX ) has sent shockwaves through the pharmaceutical industry with groundbreaking results from its experimental weight loss pill. The company's shares soared by over 25% following the announcement of positive outcomes from a small-scale study, propelling it into the forefront of the fiercely competitive weight-loss drug market. Viking's innovative once-a-day oral tablet demonstrated remarkable efficacy in aiding weight loss among participants. Over 28 days, patients who received the pill experienced an average weight loss of up to 5.3%, significantly surpassing the outcomes of those who were administered a placebo. Notably, an impressive 57% of individuals treated with Viking's pill achieved a weight reduction of at least 5%, showcasing the drug's potential to revolutionize the treatment landscape for obesity. Moreover, the trial unveiled encouraging findings regarding the durability of weight loss, with patients maintaining or even augmenting their progress six days after the cessation of the medication. Viking's CEO, Brian Lian, underscored the significance of this sustained effect, particularly for patients facing challenges in adhering to a daily regimen. "I think that's an encouraging sign that you don't necessarily have to take it every day," remarked Lian during a conference call, hinting at the flexibility and convenience offered by Viking's pioneering approach. Crucially, the trial also provided reassuring insights into the safety and tolerability of the oral drug, with the majority of reported side effects being mild and transient. Unlike some existing treatments, patients did not report vomiting, while gastrointestinal events were predominantly mild in nature—a testament to Viking's commitment to developing a well-tolerated therapy. Analysts have drawn parallels between Viking's weight loss injection and established drugs like Eli Lilly's Zepbound, highlighting their shared mechanism of action in mimicking gut hormones involved in appetite regulation and metabolic control. By leveraging the synergistic effects of GLP-1 and GIP, Viking's pill offers a multifaceted approach to weight management, distinguishing itself in a rapidly evolving landscape. As the company sets its sights on advancing to phase two trials later this year, anticipation is palpable within the investment community and among patients seeking effective and accessible solutions for obesity. With the potential to tap into a burgeoning market projected to reach $100 billion by the end of the decade, Viking Therapeutics ( NASDAQ:VKTX ) stands poised to redefine the standard of care and carve out a niche as a formidable contender in the fight against obesity-related ailments. Technical Outlook Viking Therapeutics ( NASDAQ:VKTX ) Spiked more than 25% prior to the weight loss pill data news with a positive Relative Strength Index (RSI) of 65 indicating a moderately overbought solution with a potential for further surge. In an era marked by escalating rates of obesity and metabolic disorders, Viking's groundbreaking advancements offer a glimmer of hope for millions worldwide, signaling a new dawn in the quest for sustainable weight loss solutions. As the journey unfolds, all eyes remain fixed on Viking Therapeutics, a beacon of innovation and progress in the pursuit of healthier futures.
NASDAQ:VKTXLong
by DEXWireNews
Viking Therapeutics (VKTX): 30-40%+ Long Trade OpportunityVKTX has suffered a 10%+ decline today and I believe that there is a great long trade setup forming in the buy zone (between the two light blue trendlines). The price action is still bearish at the time of writing so I would monitor the charts for a reversal on lower time frames. However, this will be a quick trade setup for me with an exit at my sell zone between the two yellow trendlines. I believe that this will be a 30-40% trade opportunity depending on where VKTX bottoms out and peaks in these two key zones. I'm seeing a lot of bullish technical analysis signs. The two most notable are the RSI reaching oversold levels and a break below the Bollinger Band. However, I do think that VKTX has a high risk of dropping hard after reaching the yellow trendline so I'm looking to make this a quick trade.
NASDAQ:VKTXLong
by realchartchamp